Attovia IPO: Shares in the biotech company, backed by Goldman Sachs, are now available

Pre-market trading in shares of Attovia Therapeutics, a small-cap developer of a treatment for chronic itching, has begun on the Freedom client trading platform. The company, founded just three years ago, is backed by Goldman Sachs Alternatives, among others. Later on August 5, the company’s shares will be listed on Nasdaq under the ticker symbol ATTO. To participate, click on the ATTO ticker.

Biotechnology company Attovia raised $289 million in its IPO on the Nasdaq. It sold 17 million shares—about 36% more than originally planned—at $17 per share (at the upper end of the previously announced price range of $15–17). As a result, the company’s total market capitalization stands at approximately $731.5 million, according to Bloomberg.

Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital served as underwriters for Attovia’s IPO. They were granted a 30-day option to purchase up to 2.55 million shares of the company.

Attovia plans to use the proceeds from the transaction to further develop its drugs and to replenish its working capital, according to the company’s IPO prospectus filed with the regulator.

Founded in 2023, the American company Attovia develops drugs for the treatment of immune-mediated diseases—those that develop due to a malfunction of the immune system. To model these diseases, the company uses a platform called Attobody, which it licensed from Alamar Biosciences in exchange for a stake in the biotech firm. Alamar Biosciences currently holds more than 5% of Attovia.

With the help of Attobody, Attovia managed to develop three drug candidates in its first two years, including ATTO-1310, which is currently in clinical trials, the company states in its IPO prospectus. ATTO-1310 is intended for the treatment of chronic pruritus and atopic dermatitis. In the first quarter of 2026, the company completed the first phase of its trials—in healthy volunteers. Two other compounds—ATTO-2306 for inflammatory skin diseases and ATTO-1091 for inflammatory bowel disease—are awaiting approval to begin clinical trials. These trials could begin in the first half of 2027.

Attovia lists Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio among its investors with a stake of at least 5%.

Goldman Sachs led a $105 million funding round for the biotech company in 2024. “In a short period of time, Attovia has built an impressive pipeline of development projects,” said Colin Walsh, Managing Director of Life Sciences Investments at Goldman Sachs Alternatives, at the time.

As of March 31, 2026, the company had raised a total of $255.8 million from leading biotechnology investors, according to its prospectus. The company does not generate revenue from its operations, and its net loss for 2025 increased by 52% to $60.6 million, the prospectus states.

The report also states that the company will not generate revenue from the sale of its drugs for quite some time. Attovia warns investors that this may never happen, as it depends on the progress of research into its drug candidates, as well as regulatory decisions regarding their approval.

Attovia's IPO is taking place amid growing investment in the biotechnology sector, according to Reuters. In late July, Apnimed, a developer of sleep apnea pills, raised $192 million in its initial public offering. In June, Kardigan, a developer of drugs for cardiovascular diseases, raised $400 million in its IPO.

The IPO of Attovia Therapeutics is a promising venture capital bet, according to IPO expert Donovan Jones in a column on Seeking Alpha. He points out that the company’s most advanced product has only just completed the first phase of clinical trials.

Attovia’s main competitive advantage lies in its platform. Among the risks associated with investing in its securities are the lack of completed clinical trials, current losses, and a high probability that the company will need additional capital, which would dilute shareholders’ stakes, according to Minichart, an information and analytical system for traders.

___________________

Freedom clients will be able to trade Standard Nuclear shares before the main trading session opens. Trading will begin in the early pre-market session 2–3 hours before the U.S. markets open (from 3:30 p.m. to 4:30 p.m. Astana time). To participate, click on the ATTO ticker.